Spondyloarthritides: evolving therapies

Table 3 Intention to treat data for infliximab, etanercept and adalimumab

		Week 0	Week 2	Week 6	Week 12	Week 24	Year 1	Year 2	Year 3
Disease measure	Drug	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
BASDAI 50	Infliximab [24, 93–95]	0	41	~58	53		47	41	47
	Etanercept [25]	0		57	71
	Adalimumab [13]	0			43	51	56	59
ASAS 20	Infliximab [37, 71]	0	~50	~61	~62	~61		74
	Etanercept [96, 97]	0	53		60	~76		83
	Adalimumab [10, 13]	0	~42	~56	58	65		65
ASAS 40	Infliximab [93, 95]	0		~32	50	47	~54	52	50
	Etanercept [97]	0			49	~64	~62		~66
	Adalimumab [13]	0		~35		46		51
ASAS 5/6	Infliximab [93]	0		~34	~63	~52	53	~48	46
	Etanercept^a [98]	0		~50	~69	~60	65
	Adalimumab [13]	0		~37	48	59	~55	59
ASAS Partial Remission	Infliximab [71]	0	~10	~17	~21	22	~23	~29
	Etanercept^a [98]	0		31	31	~27	31
	Adalimumab [13]	0		~20	21	24		34

Intention-to-treat data from randomised control trials and open-label extensions based on duration of anti-TNF therapy for infliximab, etanercept and adalimumab. ASAS, Assessment of Spondyloarthritis International Society; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index. ^aEtanercept ASAS 5/6 and partial remission intention-to-treat data are from patients recommencing etanercept after withdrawing for several months after a 6-month randomised control trial with etanercept.

ISSN: 1478-6362